To evaluate the effect of Apc001OC on bone mass and bone microarchitecture in OI mice, 6-week-old Col1a2+/G610C mice (OI) were subcutaneously administered with 25 mg/kg of Apc001OC conjugate, Apc001HC conjugate, Apc001DA conjugate, scrambledApc001OC (scApc001OC) conjugate, Apc001PE conjugate, or non-conjugated Apc001 once every 2 weeks (q2wk) for a 12-week period.12 The gene discussed is COL1A2; the disease is osteogenesis imperfecta.